Acute stroke trials: Reasons for patient withdrawal.

Area of Science:

• Neurology
• Clinical Trials
• Pharmacology

Background:

• Patient adherence and completion rates are critical for the validity and efficiency of clinical trials.
• Understanding reasons for participant withdrawal is essential for optimizing trial design and resource allocation.

Purpose of the Study:

• To analyze the primary reasons for patient withdrawal in two acute stroke clinical trials investigating calcium-channel antagonists.
• To identify factors influencing withdrawal rates and determine if trial length impacts patient dropout.

Main Methods:

• A retrospective analysis of patient data from two double-blind, placebo-controlled acute stroke trials.
• Combined data from 43 patients in a 2-week trial and 30 patients in a 3-week trial.
• Categorized withdrawal reasons including medication errors, prohibited drug use, early death, disqualifying illness, consent withdrawal, and enrollment issues.

Main Results:

• Withdrawal rates were 37% and 47% in the two trials, respectively, with similar reasons for dropout.
• Key reasons for withdrawal included medication administration errors (11%), use of prohibited drugs (7%), early death (7%), and newly discovered disqualifying illnesses (8%).
• Factors such as stroke risk factors, age, sex, and stroke severity did not significantly correlate with increased withdrawal frequency. Most withdrawals occurred early in the trials.

Conclusions:

• Early identification and management of medication administration errors and disqualifying conditions are crucial for improving patient retention in acute stroke trials.
• The relatively short duration of these trials did not appear to be a substantial factor in patient withdrawal.
• Optimizing trial protocols to minimize early-stage dropouts can enhance the reliability of results and reduce overall trial costs.